UPXI vs HIMS vs SKIN vs TDOC

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -39. 2% for Upexi, Inc. (UPXI). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 50. 3x trailing P/E (51. 5x forward), making it the more compelling value choice. Analysts rate Hims & Hers Health, Inc. (HIMS) a "Hold" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -98. 8% for Upexi, Inc. (UPXI). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus UPXI's -98. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Teladoc Health, Inc.

(TDOC) is the lower-risk stock at 1. 91β versus Upexi, Inc. 's 3. 63β — meaning UPXI is approximately 90% more volatile than TDOC relative to the S&P 500. On balance sheet safety, Upexi, Inc. (UPXI) carries a lower debt/equity ratio of 31% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -39. 2% for Upexi, Inc. (UPXI). On earnings-per-share growth, the picture is similar: Upexi, Inc. grew EPS 92. 8% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -86. 5% for Upexi, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -79. 1% for UPXI. At the gross margin level — before operating expenses — TDOC leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for SKIN: 42.

9% to $1. 30.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hims & Hers Health, Inc.

(HIMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+161. 9% 10Y return). Upexi, Inc. (UPXI) carries a higher beta of 3. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HIMS: +161. 9%, UPXI: -98. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (UPXI (Communication Services) and HIMS (Healthcare) and SKIN (Consumer Defensive) and TDOC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: UPXI is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; SKIN is a small-cap quality compounder stock; TDOC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.